Predicting the Price of Drugs Years Before Launch

OKRAOKRA, a Cambridge-based provider of Artificial Intelligence (AI) analytics for Life Sciences, has developed a new AI system to accurately predict the (a) price and (b) 'benefit outcome' of new drug molecules several years before launch. OKRA's system is the first of its kind and uses AI to deliver detailed evidence and reassurance to pharma professionals to aid the submission process, opening doors for more effective drugs to reach the market faster.

OKRA combined its AI expertise with top 5 pharma industry domain knowledge to create ValueScope, a game-changing AI system for pricing and market access executives. ValueScope enables market access and pricing teams to perform scenario analysis of 'payer negotiations', an essential part of bringing a molecule to market. ValueScope sits on top of an AI engine that is the most robust of its kind, having learnt from millions of data points including tens of thousands of clinical trial results, historic drug submissions, the latest pricing data, and HTA reports (from IQWiG and G-BA).

OKRA has validated ValueScope in Germany, achieving >90% accuracy when predicting the benefit outcome and negotiated price of Phase III treatments.

The benefits of this product are clear. The system enables market access and commercial teams to perform assessments of early drug candidates faster and more efficiently than before, without the need for extensive pricing research and repetitive data crunching. Scenarios can be built more reliably and decisions can be taken quicker and with more confidence. OKRA’s clients will be able to spend more time building realistic Target Value Propositions and delivering evidence, without wasting time on debates about whether the pricing and reimbursement will eventually work when all the clinical and economic data generation has ended. Thanks to ValueScope, pharmaceutical experts can focus on value for patients and society with the reassurance that an AI system has reliably informed them about what constitutes a fair price based on previous decisions.

"ValueScope provides intelligence that pharma executives require when critical decisions about future investments and patient access are made," said Dr Loubna Bouarfa, CEO and Founder of OKRA. "We use data to bring clarity and transparency to the table. We provide control and confidence to access experts in order to generate competitive advantage with authenticity and trust. Let’s deliver more medicines to patients with evidence that supports their real benefits and price."

For further information and to register, please visit:
https://okra.ai

About OKRA's technology

OKRA's products for market access, commercial and medical executives are built on the most sophisticated AI. Coupled with OKRA's Hybrid Explainability Engine and 'glass box' promise, the company empowers users by providing full reasoning behind every prediction.

About OKRA

At OKRA we are fostering a new generation of Artificial Intelligence (AI) solutions that support the healthcare ecosystem. Our solutions are implemented by top pharma companies throughout the product pipeline to empower employees in decision making around complex problems.

OKRA's AI solutions are translating large clinical, scientific and commercial data sets into actionable insights that employees in life science companies can easily query at their desks or whilst on the move.

We believe that for AI to truly empower people, the insights presented must be explainable and instil confidence when driving action. Our suite of products have been built in partnership with top life science companies, with a focus on empowering the people to take action.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...